Verve Therapeutics (VERV) Competitors $4.59 +0.08 (+1.77%) Closing price 04:00 PM EasternExtended Trading$4.60 +0.01 (+0.22%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERV vs. SPRY, IRON, VERA, MESO, IMCR, TVTX, INDV, EWTX, OCUL, and CALTShould you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include ARS Pharmaceuticals (SPRY), Disc Medicine (IRON), Vera Therapeutics (VERA), Mesoblast (MESO), Immunocore (IMCR), Travere Therapeutics (TVTX), Indivior (INDV), Edgewise Therapeutics (EWTX), Ocular Therapeutix (OCUL), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. Verve Therapeutics vs. ARS Pharmaceuticals Disc Medicine Vera Therapeutics Mesoblast Immunocore Travere Therapeutics Indivior Edgewise Therapeutics Ocular Therapeutix Calliditas Therapeutics AB (publ) Verve Therapeutics (NASDAQ:VERV) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, community ranking, earnings and media sentiment. Do institutionals and insiders hold more shares of VERV or SPRY? 97.1% of Verve Therapeutics shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 19.3% of Verve Therapeutics shares are held by insiders. Comparatively, 40.1% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has preferable earnings & valuation, VERV or SPRY? ARS Pharmaceuticals has higher revenue and earnings than Verve Therapeutics. Verve Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerve Therapeutics$32.33M12.61-$200.07M-$2.35-1.95ARS Pharmaceuticals$89.15M16.38-$54.37M$0.08186.00 Does the MarketBeat Community believe in VERV or SPRY? Verve Therapeutics received 8 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 86.21% of users gave ARS Pharmaceuticals an outperform vote while only 61.11% of users gave Verve Therapeutics an outperform vote. CompanyUnderperformOutperformVerve TherapeuticsOutperform Votes3361.11% Underperform Votes2138.89% ARS PharmaceuticalsOutperform Votes2586.21% Underperform Votes413.79% Does the media refer more to VERV or SPRY? In the previous week, Verve Therapeutics had 26 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 31 mentions for Verve Therapeutics and 5 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 1.56 beat Verve Therapeutics' score of 0.56 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verve Therapeutics 7 Very Positive mention(s) 4 Positive mention(s) 13 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive ARS Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more volatility & risk, VERV or SPRY? Verve Therapeutics has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Do analysts rate VERV or SPRY? Verve Therapeutics currently has a consensus target price of $25.75, suggesting a potential upside of 461.00%. ARS Pharmaceuticals has a consensus target price of $31.00, suggesting a potential upside of 108.33%. Given Verve Therapeutics' higher possible upside, equities analysts plainly believe Verve Therapeutics is more favorable than ARS Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verve Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Is VERV or SPRY more profitable? ARS Pharmaceuticals has a net margin of 0.00% compared to Verve Therapeutics' net margin of -807.65%. ARS Pharmaceuticals' return on equity of -22.56% beat Verve Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Verve Therapeutics-807.65% -35.23% -27.65% ARS Pharmaceuticals N/A -22.56%-21.82% SummaryARS Pharmaceuticals beats Verve Therapeutics on 12 of the 19 factors compared between the two stocks. Remove Ads Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERV vs. The Competition Export to ExcelMetricVerve TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$412.01M$6.48B$5.29B$7.37BDividend YieldN/A3.24%5.11%4.31%P/E Ratio-1.896.8321.7017.78Price / Sales12.74228.36378.1494.74Price / CashN/A65.6738.1534.64Price / Book0.635.876.423.98Net Income-$200.07M$142.26M$3.20B$247.33M7 Day Performance52.13%7.58%4.73%4.31%1 Month Performance-26.58%-14.16%-9.88%-7.80%1 Year Performance-31.16%-9.81%10.77%1.40% Verve Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERVVerve Therapeutics2.9233 of 5 stars$4.59+1.8%$25.75+461.0%-36.8%$407.57M$32.33M-1.87110Analyst ForecastOptions VolumeNews CoverageSPRYARS Pharmaceuticals3.0892 of 5 stars$14.47+3.0%$31.00+114.2%+62.1%$1.42B$89.15M-28.3790Positive NewsIRONDisc Medicine2.4164 of 5 stars$40.27+4.0%$93.80+132.9%+37.0%$1.39BN/A-10.1230VERAVera Therapeutics2.8929 of 5 stars$21.50-4.1%$64.67+200.8%-50.1%$1.37BN/A-8.2440MESOMesoblast2.603 of 5 stars$10.74+5.9%$18.00+67.6%+119.8%$1.36B$5.67M0.0080Positive NewsGap UpIMCRImmunocore2.3745 of 5 stars$26.92+1.2%$63.73+136.7%-47.8%$1.35B$310.20M-28.34320Analyst ForecastTVTXTravere Therapeutics2.5711 of 5 stars$14.83+2.3%$32.08+116.3%+136.9%$1.32B$233.18M-3.62460Analyst ForecastNews CoverageINDVIndivior3.78 of 5 stars$9.44+3.6%$15.00+58.9%-53.3%$1.30B$1.19B-26.971,164Upcoming EarningsShort Interest ↓Positive NewsEWTXEdgewise Therapeutics1.992 of 5 stars$12.33+8.0%$40.38+227.5%-21.6%$1.29BN/A-8.2260Gap UpOCULOcular Therapeutix3.4539 of 5 stars$7.57+6.5%$16.38+116.3%-8.0%$1.20B$63.72M-5.73230CALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180 Remove Ads Related Companies and Tools Related Companies ARS Pharmaceuticals Competitors Disc Medicine Competitors Vera Therapeutics Competitors Mesoblast Competitors Immunocore Competitors Travere Therapeutics Competitors Indivior Competitors Edgewise Therapeutics Competitors Ocular Therapeutix Competitors Calliditas Therapeutics AB (publ) Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VERV) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VERV Stock Free VERV Stock Alerts